comparemela.com

Latest Breaking News On - Tavr - Page 9 : comparemela.com

TAVR procedure helps Pro Gator Boats founder to get back to building boats

SHREVEPORT, La — Richard Leroy Moore has a family history of heart-related issues.

MedCity Pivot podcast: Reflecting on the 10-year anniversary of FDA s approval of transcatheter aortic valve replacement

Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery. This episode of Pivot features Larry Wood, corporate vice president for TAVR with Edwards, who reflects on the journey.

Mit der Marktzulassung des Transkatheter-Aortenklappenersatzsystems der zweiten Generation führt Peijia Medical China in die Rückführbare Ära mit TAVR-Produkten

(2) Suzhou, China (ots/PRNewswire) - Das von Peijia Medical (9996. HK) entwickelte TaurusElite® Transkatheter-Aortenklappenersatzsystem (im Folgenden als TaurusElite® bezeichnet) ist von der National Medical Products Administration (NMPA) im Juni 2021 zur Vermarktung zugelassen worden (Reg.-Nr. GXZZ 20213130464). Diese Zulassung wird den Übergang der chinesischen TAVR-Praxis in die rückführbare Ära beschleunigen. TaurusElite® ist das TAVR-System der zweiten Generation, das von Peijia Medical entwickelt wurde. Es ist außerdem das zweite und das neueste rückführbare TAVR-System, das in China zugelassen ist. Ähnlich wie das Design von TaurusOne® verwendet TaurusElite® bovines Material für die Aortenklappenprothese und verfügt über eine ideale radiale Abstützung und Flexibilität, die die große Patientenkohorte in China mit starker Aortenklappenverkalkung, bikuspiden Aortenklappen und anderen derartigen Läsionen berücksichtigt hat. TaurusElite® wird von den Fors

Overcoming disparities in access to care for communities of color

This year, more than 5 million Americans will be diagnosed with Heart Valve Disease. All too often, for Black patients with certain forms of the disease this can be a death sentence, with patients from minority communities facing significantly higher mortality rates than their white counterparts. The most common form of this disease is aortic stenosis (AS), where the aortic valve narrows and weakens the heart. While common, AS can be deadly, and one in six patients will have a more aggressive form called symptomatic severe aortic stenosis (SSAS), that can be fatal within two years without treatment. Diseases like SASS and other chronic diseases lay bare stark inequities in our health care system, in which our Black patients are disproportionately impacted. When we see patients with SSAS, treatment options include two approaches to repair their failing valve, one that involves open-heart surgery and one that is minimally invasive. The latter, transcatheter aortic valve replacement (TAV

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.